At a glance

What is acetyl hexapeptide-8?

Acetyl hexapeptide-8 is a synthetic six-amino acid peptide used as a cosmetic ingredient, best known by the trade name Argireline. It is also called acetyl hexapeptide-3, an older name for the same molecule. Its sequence is patterned on the end of SNAP-25¹, a protein that nerves use to release the signals that make muscles contract.

It is sold in serums and creams marketed for anti-aging, and it is applied topically to the skin.

How does it work?

Acetyl hexapeptide-8 softens the look of expression lines by reducing the small muscle contractions that create them. Nerves trigger those contractions by releasing a chemical signal, and that release depends on a group of proteins called the SNARE complex¹, of which SNAP-25 is a part. In laboratory studies, acetyl hexapeptide-8 mimics the end of SNAP-25 and competes with it, which interferes with SNARE complex formation and reduces the release of the signal that tells the muscle to contract. This is the same broad target as Botox, but acetyl hexapeptide-8 is applied topically and is far milder, not an injection that blocks the nerve.

One important limit is delivery. Because it is a relatively large, water-loving peptide, how well it crosses the skin barrier to reach the nerves underneath is debated², and that penetration question is a major reason its effect is modest.

Is it FDA-approved?

No, and it does not need to be. The FDA does not approve cosmetics³ or most cosmetic ingredients before they go on the market. Cosmetics are regulated and must be safe when used as directed and properly labeled, but there is no pre-market approval step the way there is for drugs, so no anti-aging peptide in a serum is "FDA-approved."

The line that actually matters for an ingredient like this is the difference between a cosmetic and a drug⁴. A product is a cosmetic when it is intended to improve appearance, but if it claims to change the structure or function of the skin, such as a claim to paralyze muscles, the FDA can regulate it as an unapproved drug. This is why skincare claims are written around the appearance of lines rather than a promised physiological change.

What is it used for?

Acetyl hexapeptide-8 is used almost entirely in topical anti-aging products. It is included to soften the appearance of expression lines and wrinkles, especially forehead lines and the crow's feet around the eyes. It is one of the most common peptide ingredients in over-the-counter skincare.

What does the research show?

The main controlled evidence is a 2013 randomized, placebo-controlled study¹ in 60 people, in which a topical argireline product reduced the appearance of peri-orbital wrinkles over four weeks compared with placebo. A 2025 review² and other small studies report similar modest improvements, while noting that many studies are small or manufacturer-associated and that skin penetration is a genuine question. The research supports a modest cosmetic benefit, not a result like injectable Botox.

What are the side effects?

Topical acetyl hexapeptide-8 is generally well tolerated, and a cosmetic-industry safety review⁵ assessed it as safe as used in cosmetics. As with any skincare ingredient, some people can still experience:

• Mild redness
• Irritation
• An allergic reaction

For that reason, a patch test before regular use is sensible. Because the peptide is applied to the skin rather than injected, its safety considerations are those of a typical cosmetic ingredient.

Frequently asked questions

Is argireline the same as Botox?

No. Botulinum toxin A is injected directly into the target muscle, where it enzymatically cleaves SNAP-25⁶ and produces a true, long-lasting neuromuscular blockade that reverses only slowly as nerve connections to the muscle recover. Argireline is a topical cosmetic peptide that, according to its proposed mechanism, interferes with SNARE complex assembly. The mechanisms are fundamentally different, and whether argireline reaches neuromuscular junctions in meaningful concentrations through topical application is debated. Marketing argireline as "topical Botox" overstates what the evidence supports.

Does argireline actually work for wrinkles?

The evidence is mixed. A randomized, placebo-controlled trial published in 2013 found significant improvements in periorbital wrinkles⁷ after 28 days of twice-daily argireline application in 60 subjects. An independent 2023 split-face study of 19 women using objective Visia analysis found no significant wrinkle reduction⁸. No large, long-duration, independently conducted RCT has confirmed efficacy. Modest effects under specific formulation conditions are plausible given the mechanistic data; established efficacy equivalent to retinoids or injected botulinum toxin is not supported by the current evidence base.

Why doesn't argireline penetrate the skin effectively?

Argireline is a hydrophilic peptide with a molecular weight of approximately 889 daltons⁹. The stratum corneum is a lipid-rich barrier that preferentially impedes the passage of large, polar, water-soluble molecules. In laboratory penetration tests on human cadaver and guinea pig skin, most applied argireline washed off the surface¹⁰, the portion that penetrated stayed mostly in the stratum corneum, only about 0.01% reached the epidermis, and no peptide was detected in the dermis. Reaching neuromuscular junctions, which are located in muscle tissue beneath the dermis, would require substantially greater tissue penetration than has been demonstrated.

What concentration of argireline do commercial products contain?

Commercial cosmetics typically contain argireline at low concentrations. The Cosmetic Ingredient Review Expert Panel, in a 2025 assessment, found argireline safe at concentrations up to 0.005%¹¹ in present practices of use. Some efficacy studies describe formulations containing 10% of the hexapeptide¹², which is orders of magnitude higher. A 2021 analysis of commercial creams and serums detected argireline alongside its oxidized form¹³, because its methionine residue can oxidize, which raises questions about product stability. The gap between clinical trial concentrations and typical commercial use concentrations is relevant to evaluating real-world product claims.

Is argireline safe to use?

Across published studies, argireline has shown a low-irritation profile. Early testing found no primary irritation at high doses¹², and no allergic reactions were reported in a 26-patient case series¹⁴ or a small 2023 double-blind study⁸. The CIR Expert Panel formally assessed acetyl hexapeptide-8 amide as safe for cosmetic use¹¹ at concentrations up to 0.005% in its 2025 assessment. The safety profile is one of argireline's genuine strengths relative to injected botulinum toxin, which carries risks including eyelid ptosis and headache⁶.

How does argireline compare to Matrixyl (palmitoyl pentapeptide)?

Matrixyl (pal-KTTKS)¹⁵ is a signal peptide designed to stimulate collagen production¹⁶ in the dermis. Argireline is a neurotransmitter-inhibitor peptide that attempts to modulate SNARE complex assembly and reduce muscle contraction signals. The mechanisms are entirely different. Both face the skin penetration barrier, but signal peptides targeting dermal fibroblasts have a less extreme distance to travel than peptides attempting to reach neuromuscular junctions in underlying muscle. A 2005 placebo-controlled, split-face trial in 93 women found statistically significant wrinkle reductions with pal-KTTKS, though that evidence base is similarly small-scale and requires independent replication. Neither ingredient has an evidence base comparable to topical retinoids.

Can formulation improvements help argireline penetrate the skin?

Possibly. In pig-skin experiments, water-in-oil-in-water multiple emulsions significantly increased¹⁷ argireline skin penetration compared to simpler emulsion types. A 2018 study showed that molecular modifications to argireline analogs⁹ can improve human skin permeation in vitro, with one modified variant reducing glutamate release by 43% in a neural cell model. As of September 2026, no modified or delivery-enhanced argireline formulation has completed a placebo-controlled clinical trial demonstrating superior efficacy to standard commercial formulations. Formulation science is the active frontier for this ingredient.

More for skin & aging